Minervax Announces 72M Eur Financing To Advance Development Of Novel Vaccine Against Group B Streptococcus
Round Type
Funding Round
CopenhagenBiotechnologyInvestors
Description
MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the successful completion of a 72 million EUR financing round. The equity financing of 22 million EUR was co-led by new investors Trill Impact Ventures and Pureos Bioventures and includes existing investors REPAIR Impact Fund (Novo Holdings), Sunstone Life Science Ventures, LF Investment, Wellington Partners, Sanofi Ventures, Adjuvant Capital and Industrifonden. In addition to the equity financing, the European Investment Bank provided a 50 million EUR loan facility.
Quick answer
MinervaX raised an undisclosed amount in a Funding Round round, dated December 15, 2022. Investors: European Investment Bank, Adjuvant Capital, Sanofi Ventures, Wellington Partners, LF Investment, Repair Impact Fund, Pureos Bioventures and Trill Impact Ventures. MinervaX is based in Copenhagen, Capital Region Of Denmark, Denmark.
- How much did MinervaX raise?
- MinervaX raised an undisclosed amount in a Funding Round round on December 15, 2022.
- Who invested in MinervaX?
- European Investment Bank, Adjuvant Capital, Sanofi Ventures, Wellington Partners, LF Investment, Repair Impact Fund, Pureos Bioventures and Trill Impact Ventures are named as investors in this round.
- What does MinervaX do?
- MinervaX is a Danish biotechnology company, established in 2010 to develop a prophylactic vaccine against Group B Streptococcus (GBS), based on research from Lund University.
- Where is MinervaX based and how big is it?
- MinervaX is based in Copenhagen, Capital Region Of Denmark, Denmark.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as MinervaX that raised within 45 days of this round, from Fundz verified event records.
- Enzene raised $50M (Funding Round) on January 29, 2023.
- Alloplex Biotherapeutics, Inc. raised $21M on January 27, 2023.
- Grey Wolf Therapeutics raised $49M (Funding Round) on January 27, 2023.
- Inhibikase Therapeutics raised $4.2M (Seed) on January 27, 2023.
- Colossal Biosciences raised $163M on January 27, 2023.
- Avenzo Therapeutics raised $243K (Pre-Seed) on January 27, 2023.
Who to call at MinervaX, and when
A new round usually means MinervaX is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day MinervaX raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at MinervaX, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at MinervaX. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment MinervaX raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
MinervaX raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.